4744-94-9Relevant academic research and scientific papers
Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's disease
Meden, An?e,Knez, Damijan,Juki?, Marko,Brazzolotto, Xavier,Gr?i?, Marija,Pi?lar, Anja,Zahirovi?, Abida,Kos, Janko,Nachon, Florian,Svete, Jurij,Gobec, Stanislav,Gro?elj, Uro?
, p. 3765 - 3768 (2019/04/01)
We have identified tryptophan-based selective nanomolar butyrylcholinesterase (BChE) inhibitors. They are defined according to their chemical modularity, novel binding mode revealed by five solved crystal structures with human BChE, low cytotoxicity, and predicted permeability of the blood-brain barrier. Altogether, these factors indicate their potential as unique lead compounds for symptomatic therapy against Alzheimer's disease.
Conformationally constrained [p-(ω-aminoalkyl)phenacetyl]-L-seryl-L- lysyl dipeptide amides as potent peptidomimetic inhibitors of Candida albicans and human myristoyl-CoA:protein N-myristoyl transferase
Nagarajan, Srinivasan R.,Devadas, Balekudru,Zupec, Mark E.,Freeman, Sandra K.,Brown, David L.,Lu, Hwang-Fun,Mehta, Pramod P.,Kishore, Nandini S.,McWherter, Charles A.,Getman, Daniel P.,Gordon, Jeffrey I.,Sikorski, James A.
, p. 1422 - 1438 (2007/10/03)
MyristoylCoA:protein N-myristoyltransferase (NMT) covalently attaches the 14-carbon saturated fatty acid myristate, via an amide bond, to the N- terminal glycine residues of a variety of cellular proteins. Genetic studies have shown that NMT is essential
